2004中国免疫学杂志:英文版Requires access

Anti-CD137 Monoclonal Antibody Promotes the Direct Anti-Tumor Effect Mediated by Peripheral Blood-Derived Human Dendritic Cells in vitro

Li-NingZhang, QunWang, Xiao-YanWang, PeifangDing, Jing-Song, Chun-HongMa, Wen-ShengSun

Open publisher page 0 citations

Abstract

CD137, a costimulatory factor of TNFR family, is expressed on activated T cells and freshly isolated mouse dendritic cells (DCs). To date, there are only limited data dealing with the expression and the effect of CD137 on human DCs. We report in this work that CD137 can coexpress with CD137L on immature peripheral blood-derived human DCs (9.77%). The mature DCs stimulated by LPS showed a much higher level of CD137 expression (36.06%). Ligation of CD137 on the surface of DCs with anti-CD137 monoclonal antibody (mAb)could enhance the direct anti-tumor effect mediated by human DCs in vitro. The agonistic anti-CD137 mAb was able to elevate by about 20% of the DC-mediated inhibition of tumor growth in five tumor cell lines. These results indicate that the appliance of anti-CD137 mAb might be used as a new strategy for tumor immunotherapy. Cellular & Molecular Immunology. 2004;1(1):71-76.

About this research paper

What this paper is about

CD137, a costimulatory factor of TNFR family, is expressed on activated T cells and freshly isolated mouse dendritic cells (DCs). To date, there are only limited data dealing with the expression and the effect of CD137 on human DCs. We report in this work that CD137 can coexpress with CD137L on immature peripheral blood-derived human DCs (9.77%). The mature DCs stimulated by LPS showed a much higher level of CD137 expression (36.06%). Ligation of CD137 on the surface of DCs with anti-CD137 monoclonal antibody (mAb)could enhance the direct anti-tumor effect mediated by human DCs in vitro. The agonistic anti-CD137 mAb was able to elevate by about 20% of the DC-mediated inhibition of tumor growth in five tumor cell lines. These results indicate that the appliance of anti-CD137 mAb might be used as a new strategy for tumor immunotherapy. Cellular & Molecular Immunology. 2004;1(1):71-76.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

CD137, a costimulatory factor of TNFR family, is expressed on activated T cells and freshly isolated mouse dendritic cells (DCs). To date, there are only limited data dealing with the expression and the effect of CD137 on human DCs. We report in this work that CD137 can coexpress with CD137L on immature peripheral blood-derived human DCs (9.77%). The mature DCs stimulated by LPS showed a much higher level of CD137 expression (36.06%). Ligation of CD137 on the surface of DCs with anti-CD137 monoclonal antibody (mAb)could enhance the direct anti-tumor effect mediated by human DCs in vitro. The agonistic anti-CD137 mAb was able to elevate by about 20% of the DC-mediated inhibition of tumor growth in five tumor cell lines. These results indicate that the appliance of anti-CD137 mAb might be used as a new strategy for tumor immunotherapy. Cellular & Molecular Immunology. 2004;1(1):71-76.

Key concepts: CD137, Monoclonal antibody, Dendritic cell, In vitro, Follicular dendritic cells, Immunotherapy, Cancer research, Antibody

Related papers

Back to paper searchBrowse research topicsOriginal source
Anti-CD137 Monoclonal Antibody Promotes the Direct Anti-Tumor Effect Mediated by Peripheral Blood-Derived Human Dendritic Cells in vitro — Research Paper | ScholarLens